Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Eptinezumab-jjmr (Vyepti)

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)FDA safety resources (1)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

eptinezumab-jjmr - VYEPTI® (opens in a new tab)Original source URL: https://globalrph.com/dilution/eptinezumab-jjmr-vyepti/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/eptinezumab-jjmr-vyepti/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:46:38.941910+00:00
Source location
div.post-content
Packaged content SHA-256
a6610c720398fa2da1ffd1086d1a221168a64b37666d81ae54d9a859ac4520fe
Original response SHA-256
573979a8f3173c5cdfd39c89729c57f321fef28fb2e14bfd4569afd3b8077b9c
Source body SHA-256
f4d6c66b65e1298ff8350e1f3cf99d2282ee40b4f6182869364a99228a086fa3

eptinezumab-jjmr - VYEPTI® injection

PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

NS

Standard Dilutions [Amt of drug] [Infusion vol] [Infusion rate] Return to article top

[ 100mg ] [100 ml ] [30 minutes]
[ 300mg ] [100 ml ] [30 minutes]

The recommended dosage is 100 mg administered by intravenous infusion every 3 months. Some patients may benefit from a dosage of 300 mg administered by intravenous infusion every 3 months.

Use an intravenous infusion set with a 0.2 micron or 0.22 micron in-line or add-on sterile filter. After the infusion is complete, flush the line with 20 mL of 0.9% Sodium Chloride Injection, USP.

VYEPTI requires dilution prior to administration. Dilute only in 100 mL 0.9% Sodium Chloride Injection, USP. The infusion bags must be made of polyvinyl chloride (PVC), polyethylene (PE), or polyolefin (PO).

Storage and Handling of Diluted Product
Gently invert the VYEPTI solution to mix completely. Do not shake. Following dilution, VYEPTI solution must be infused within 8 hours. During this time, VYEPTI solution should be stored at room temperature, 20°C to 25°C (68°F to 77°F). Do not freeze.

Infusion Administration Instructions
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the liquid contains visible particulate matter or is cloudy or discolored.

No other medications should be administered through the infusion set or mixed with VYEPTI. VYEPTI is for intravenous infusion only; infuse over approximately 30 minutes. Do not administer VYEPTI as an intravenous push or bolus injection.

Description:
Eptinezumab-jjmr is a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand. Eptinezumab-jjmr has an approximate molecular weight of 143 kD. Eptinezumab-jjmr is produced in Pichia pastoris yeast cells by recombinant DNA technology.

VYEPTI (eptinezumab-jjmr) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to brownish-yellow solution, for intravenous infusion. VYEPTI is supplied as a 100 mg/mL single-dose vial. Each mL contains 100 mg eptinezumab-jjmr formulated in L-histidine (1 mg), L-histidine hydrochloride monohydrate (2.8 mg), polysorbate 80 (0.15 mg), sorbitol (40.5 mg), and Water for Injection, USP, at a pH of 5.8.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:

Eptinezumab-jjmr is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

INDICATIONS AND USAGE Return to article top

INDICATIONS AND USAGE:
VYEPTI is indicated for the preventive treatment of migraine in adults.

CONTRAINDICATIONS Return to article top

Contraindications:

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients in VYEPTI. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS:
Hypersensitivity Reactions
Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and institute appropriate therapy

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:

The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity.

To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication Guide. Drug information

DOSAGE AND ADMINISTRATION Return to article top

DOSAGE AND ADMINISTRATION:
2.1 Recommended Dosing
The recommended dosage is 100 mg administered by intravenous infusion every 3 months. Some patients may benefit from a dosage of 300 mg administered by intravenous infusion every 3 months.

2.2 Dilution Instructions
VYEPTI requires dilution prior to administration. Dilute only in 100 mL 0.9% Sodium Chloride Injection, USP. The infusion bags must be made of polyvinyl chloride (PVC), polyethylene (PE), or polyolefin (PO). Use appropriate aseptic technique when preparing VYEPTI solution for intravenous infusion. VYEPTI single-dose vials contain no preservative; discard unused portion remaining in the vial.

Dilution

100 mg dose:
To prepare the solution, withdraw 1 mL of VYEPTI from a single-dose vial using a sterile needle and syringe. Inject the 1 mL content into a 100 mL bag of 0.9% Sodium Chloride Injection, USP.

300 mg dose:
To prepare the solution, withdraw 1 mL of VYEPTI from each of 3 single-dose vials using a sterile needle and syringe. Inject the resulting 3 mL content into a 100 mL bag of 0.9% Sodium Chloride Injection, USP.

Storage and Handling of Diluted Product
Gently invert the VYEPTI solution to mix completely. Do not shake. Following dilution, VYEPTI solution must be infused within 8 hours. During this time, VYEPTI solution should be stored at room temperature, 20°C to 25°C (68°F to 77°F). Do not freeze.

2.3 Infusion Administration Instructions
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the liquid contains visible particulate matter or is cloudy or discolored.

No other medications should be administered through the infusion set or mixed with VYEPTI. VYEPTI is for intravenous infusion only; infuse over approximately 30 minutes. Do not administer VYEPTI as an intravenous push or bolus injection. Use an intravenous infusion set with a 0.2 micron or 0.22 micron in-line or add-on sterile filter. After the infusion is complete, flush the line with 20 mL of 0.9% Sodium Chloride Injection, USP.

DOSAGE FORMS AND STRENGTHS:
VYEPTI is a clear to slightly opalescent, colorless to brownish-yellow solution available as follows:

Injection: 100 mg/mL in a single-dose vial

Storage and Stability Return to article top

16.1 How Supplied
VYEPTI (eptinezumab-jjmr) injection is a clear to slightly opalescent, colorless to brownish-yellow solution supplied as:

Carton containing one 100 mg/mL single-dose vial - NDC 67386-130-51.

16.2 Storage and Handling
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. Do not freeze or shake.

The vial stopper is not made with natural rubber latex.

Open this historical article on its own

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

VYEPTI® - eptinezumab-jjmr (opens in a new tab)Original source URL: https://globalrph.com/dilution/vyepti-eptinezumab-jjmr/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/vyepti-eptinezumab-jjmr/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:50:26.933333+00:00
Source location
div.post-content
Packaged content SHA-256
2bc4cc43c0d79489ac3a1666765974fa5a90ae9d9b421e345b19750893d22aff
Original response SHA-256
594a293b01ef3e118836ad0e8db89adf634d70f2564a789a32ab6dea8a80e080
Source body SHA-256
bcf5b82d113841d04bdcdaddce2e023933aaad4fb1207fba70a9697049853c8b

VYEPTI® - eptinezumab-jjmr injection

PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

NS

Standard Dilutions [Amt of drug] [Infusion vol] [Infusion rate] Return to article top

[ 100mg ] [100 ml ] [30 minutes]
[ 300mg ] [100 ml ] [30 minutes]

The recommended dosage is 100 mg administered by intravenous infusion every 3 months. Some patients may benefit from a dosage of 300 mg administered by intravenous infusion every 3 months.

Use an intravenous infusion set with a 0.2 micron or 0.22 micron in-line or add-on sterile filter. After the infusion is complete, flush the line with 20 mL of 0.9% Sodium Chloride Injection, USP.

VYEPTI requires dilution prior to administration. Dilute only in 100 mL 0.9% Sodium Chloride Injection, USP. The infusion bags must be made of polyvinyl chloride (PVC), polyethylene (PE), or polyolefin (PO).

Storage and Handling of Diluted Product
Gently invert the VYEPTI solution to mix completely. Do not shake. Following dilution, VYEPTI solution must be infused within 8 hours. During this time, VYEPTI solution should be stored at room temperature, 20°C to 25°C (68°F to 77°F). Do not freeze.

Infusion Administration Instructions
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the liquid contains visible particulate matter or is cloudy or discolored.

No other medications should be administered through the infusion set or mixed with VYEPTI. VYEPTI is for intravenous infusion only; infuse over approximately 30 minutes. Do not administer VYEPTI as an intravenous push or bolus injection.

Description:
Eptinezumab-jjmr is a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand. Eptinezumab-jjmr has an approximate molecular weight of 143 kD. Eptinezumab-jjmr is produced in Pichia pastoris yeast cells by recombinant DNA technology.

VYEPTI (eptinezumab-jjmr) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to brownish-yellow solution, for intravenous infusion. VYEPTI is supplied as a 100 mg/mL single-dose vial. Each mL contains 100 mg eptinezumab-jjmr formulated in L-histidine (1 mg), L-histidine hydrochloride monohydrate (2.8 mg), polysorbate 80 (0.15 mg), sorbitol (40.5 mg), and Water for Injection, USP, at a pH of 5.8.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:

Eptinezumab-jjmr is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

INDICATIONS AND USAGE Return to article top

INDICATIONS AND USAGE:
VYEPTI is indicated for the preventive treatment of migraine in adults.

CONTRAINDICATIONS Return to article top

Contraindications:

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients in VYEPTI. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS:
Hypersensitivity Reactions
Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and institute appropriate therapy

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:

The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity.

To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication Guide. Drug information

DOSAGE AND ADMINISTRATION Return to article top

DOSAGE AND ADMINISTRATION:
2.1 Recommended Dosing
The recommended dosage is 100 mg administered by intravenous infusion every 3 months. Some patients may benefit from a dosage of 300 mg administered by intravenous infusion every 3 months.

2.2 Dilution Instructions
VYEPTI requires dilution prior to administration. Dilute only in 100 mL 0.9% Sodium Chloride Injection, USP. The infusion bags must be made of polyvinyl chloride (PVC), polyethylene (PE), or polyolefin (PO). Use appropriate aseptic technique when preparing VYEPTI solution for intravenous infusion. VYEPTI single-dose vials contain no preservative; discard unused portion remaining in the vial.

Dilution

100 mg dose:
To prepare the solution, withdraw 1 mL of VYEPTI from a single-dose vial using a sterile needle and syringe. Inject the 1 mL content into a 100 mL bag of 0.9% Sodium Chloride Injection, USP.

300 mg dose:
To prepare the solution, withdraw 1 mL of VYEPTI from each of 3 single-dose vials using a sterile needle and syringe. Inject the resulting 3 mL content into a 100 mL bag of 0.9% Sodium Chloride Injection, USP.

Storage and Handling of Diluted Product
Gently invert the VYEPTI solution to mix completely. Do not shake. Following dilution, VYEPTI solution must be infused within 8 hours. During this time, VYEPTI solution should be stored at room temperature, 20°C to 25°C (68°F to 77°F). Do not freeze.

2.3 Infusion Administration Instructions
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the liquid contains visible particulate matter or is cloudy or discolored.

No other medications should be administered through the infusion set or mixed with VYEPTI. VYEPTI is for intravenous infusion only; infuse over approximately 30 minutes. Do not administer VYEPTI as an intravenous push or bolus injection. Use an intravenous infusion set with a 0.2 micron or 0.22 micron in-line or add-on sterile filter. After the infusion is complete, flush the line with 20 mL of 0.9% Sodium Chloride Injection, USP.

DOSAGE FORMS AND STRENGTHS:
VYEPTI is a clear to slightly opalescent, colorless to brownish-yellow solution available as follows:

Injection: 100 mg/mL in a single-dose vial

Storage and Stability Return to article top

16.1 How Supplied
VYEPTI (eptinezumab-jjmr) injection is a clear to slightly opalescent, colorless to brownish-yellow solution supplied as:

Carton containing one 100 mg/mL single-dose vial - NDC 67386-130-51.

16.2 Storage and Handling
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. Do not freeze or shake.

The vial stopper is not made with natural rubber latex.

Open this historical article on its own

FDA safety resources for this medication (1)
  • FDA AEMS Q2 2026: Arthralgia - evaluating regulatory action (status 2026-09-04) (opens in a new tab)
    Dated FDA status and source scope

    Potential-signal tables are safety-review resources. Inclusion alone does not establish causality or a treatment change.

    FDA table status date: 2026-09-04

    Status in that table: FDA is evaluating the need for regulatory action.

    Exact table location: April - June 2026 safety table, data row 8 (header excluded): Product Name / Product Class = Calcitonin gene-related peptide (CGRP) inhibitors Aimovig (erenumab-aooe) injection Ajovy (fremanezumab-vfrm) injection Emgality (galcanezumab-gnlm) injection Nurtec ODT (rimegepant) orally disintegrating tablets Qulipta (atogepant) tablets Ubrelvy (ubrogepant) tablets Vyepti (eptinezumab-jjmr) injection Zavzpret (zavegepant) nasal spray; Signal = Arthralgia; Additional Information (as of 2026-09-04)

    Scope: Matches the expressly listed product/ingredient for safety-resource navigation only. It does not reconcile a stocked manufacturer, package NDC, lot or full monograph and does not establish causality. Vyepti injection is expressly listed within the CGRP group; this is not a class-membership inference.

Read the linked communication and current prescribing information before use. Resource dates and affected product scopes differ; a listed resource is not a full monograph or a lot-specific clearance.

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      eptinezumab-jjmr-vyepti
      Source IDH51-D1F7EB80D77875BE7A088EAE
      Generic name
      Eptinezumab-jjmr (Vyepti)
      Source IDH51-477960BC4302894FFE93A60B
      Class
      Biologics and immunotherapy
      Source IDH51-50073B519B0EBAF5B08135EB
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-42C15E760EE9DC89EB730C82
      Primary uses
      1. The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic.
        Source IDH51-7ADA61F084ADEC435E390EEA
      Mechanism
      Binds calcitonin gene-related peptide ligand and blocks CGRP pathway activation.
      Source IDH51-AAB0A3264827D8B3EF1DD75C
      Mechanism level
      drug_specific
      Source IDH51-F8397349F29C9EE70800F46A
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-7DEEBF25D4E512066986A386
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-48ACD05A7B1893606E222F3B
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-E6A91DBAA0C858413E82C228
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-C5C82C95AC58A3414925DD1C
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-AB4B1A35E05F35266DD055DB
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-E4A181800F1C329E1B70EC8B
      Legacy title
      Eptinezumab-jjmr (Vyepti)
      Source IDH51-4F74D64AE9EA5BC313C36087
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-BDCE7E44671FEF0EFFD91CD1
      Search text
      Eptinezumab-jjmr (Vyepti) Biologics and immunotherapy Legacy GlobalRPh directory entry The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic. Binds calcitonin gene-related peptide ligand and blocks CGRP pathway activation. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-BD400C22D2FBB92B4A5EB627
      Official access mode
      none
      Source IDH51-1908A5574D2934C9F89554B2
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-CDAE8F531B8588616D6FBEDB

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-90C37D682DE4D3888CD0341E
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-1CEB4A93CF34F000928D79BC
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-FC0832D0B96C9FEEACBEFC26

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-4C116D25801378FCEBB3A76D

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-BB632C0587108D6DA6DE2733
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      eptinezumab-jjmr-vyepti
      Source IDH51-594F68E5EE4E9D490E482C8C
      Legacy title
      Eptinezumab-jjmr (Vyepti)
      Source IDH51-F64756A931816E22606A4620
      Generic name
      Eptinezumab-jjmr (Vyepti)
      Source IDH51-4FAEAEB2F7E05681417703CB
      Class
      Biologics and immunotherapy
      Source IDH51-E898EC5C8DE5853D01508B2C
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-3BCD97073B60A8036018AF4D
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-DDC1DCD2011D5A40FEC42BD5
      Populations
      1. Population not yet normalized
        Source IDH51-A29A5516FD4032EE55F19B81
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-6B6D15A2ECCF10EFB1818CD2
      High alert
      false
      Source IDH51-206AFBC20030A42A963C668A
      Hazardous
      false
      Source IDH51-17C8EED5CB1EF43F61728D03
      Status
      Legacy migration
      Source IDH51-C6E311A03CC827E68A1F5708
      Version added
      Legacy
      Source IDH51-131BA7FED81EBA0E25D72BA5
      Sources
      LabelUrlKind
      Source IDH51-14C9AC35A1DE38F2FCB24D79
      GlobalRPh legacy IV dilution monograph
      Source IDH51-178C53491CEE224E368E7BC4
      		legacy:auto
      Source IDH51-56E5FA2D3E77AB76F36318C6
      		Legacy
      Source IDH51-266D9C78B30D88FFA4FCFC07
      Clinical release verification
      Audit version
      3.4
      Source IDH51-1AB47AEBD43CF4168175181A
      Audited on
      2026-08-30
      Source IDH51-6D9CE9718B3315EFC16E7D02
      Level
      red
      Source IDH51-9DB8F90E8DD35BB7E239357B
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-DE5AF82C8C17F312C1C64BF7
      Exact current label candidate
      false
      Source IDH51-119323EC67DED8A1B3EF3AD1
      Reference url count
      0
      Source IDH51-4BAC23418278D40C91ED303C
      Broken reference count
      0
      Source IDH51-18953901FCAC74122AEBA220
      Point of use confirmation required
      true
      Source IDH51-0FB2C492D9BEF0B1E4EBB75E
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-80CBA38395147821762BAC3F

      Dosing source fields

      Id
      eptinezumab-jjmr-vyepti
      Source IDH51-A38E94AC6787038FCAAC4056
      Generic name
      Eptinezumab-jjmr (Vyepti)
      Source IDH51-AF7C6747E3EE4F3894240E78
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-D7335067303300DADF1927AB
      Package insert
      Query name
      Eptinezumab-jjmr
      Source IDH51-D977A6BA20AF0CF24FC5015C
      Product and route must match
      true
      Source IDH51-5329624DB95234E6C21EE4B3
      Live current label enabled
      false
      Source IDH51-F20F182D97650847DF6C98B3
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-965813E77E6D4BDECA73B31E
      Direct official label access enabled
      true
      Source IDH51-019DCCBA1811E0AEAE4E2A99
      Outbound server request required
      false
      Source IDH51-E9274F898919C9C42CB24EB1
      Local summary status
      not_bundled
      Source IDH51-75CB915461A2CBA441BC33A2
      Clinical review
      Locally normalized
      false
      Source IDH51-6B60607C5C8F3AEEB1BD038A
      Reviewed
      2026-08-29
      Source IDH51-76BA05B799782F8FB3D94CE1
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-9F034074BD38E904C9D66C7B
      Clinical release verification
      Audit version
      3.4
      Source IDH51-AB7C76EF91DEA0D2803BF18D
      Audited on
      2026-08-30
      Source IDH51-BB5FC93B9AEEE780BF9F7F73
      Level
      red
      Source IDH51-9DBC2B91BCB9424DD8BDB396
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-2072EDE87CD024C971A0DF33
      Exact current label candidate
      false
      Source IDH51-32A3AA023A8E9EBFD831DB38
      Reference url count
      0
      Source IDH51-E8B0D6B2CBF30539C08D374F
      Broken reference count
      0
      Source IDH51-3B3392E714B1F9FFA7B1C8E7
      Point of use confirmation required
      true
      Source IDH51-D72469B58C3FA4EE84A53586
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-AA4337305F0FB597DFB277DE
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      eptinezumab-jjmr-vyepti
      Source IDH51-864272F705D894EDDDFAFB5B
      Name
      Eptinezumab-jjmr (Vyepti)
      Source IDH51-D6A030D5226E01E198D7D57F
      Therapeutic class
      Biologics and immunotherapy
      Source IDH51-60B82AD5AECDA1AA790608D3
      Review version
      3.1
      Source IDH51-4BAFD1F174CE1A3581C6F2A6
      Review date
      2026-08-30
      Source IDH51-6D071B7FB22D49DAB2C8DA93
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-AEE3FB4037D51700CD90F194
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-A98CE5EB42AA14D489F4B37A
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-5F0B841BC96E1E7549DD4FAB
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-D96A64B1C2924D44E29D68EF
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-DC3FA7C31106E8A983212443
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-890D450EABD273CB429E95A3
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-106CE05665694ED2907ACE3D
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-2A08C0CD71401E8101861C96
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-CCFFD0B6CDCE5BAE88741127
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-2DEEF991E353F2E250005EC7
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-284DCDD9C45CA2AA49D83D1A
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-4B8C5C5772EB882F1B91AFC9
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-32D86513BD8F81F1C0CD059B
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-5F2EF6682D5D0F458C39F553
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-9847130F5130DB51924B7378
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-5F0037EC786529A99498E78B
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-776E694321A699820316D2CB
      Adult dosing range
      Primary
      not_found
      Source IDH51-FEEF4EFD8B461F916411E74B
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-ABF9E69EE1E8F8C86473451B
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-A4B1922CABA926A32BA30A9B
      Infusion time
      Primary
      not_found
      Source IDH51-68A28FA336C07BEB65B55FC0
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-0339336F5316B11C025E8DFF
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-AC5CAC758E90714ACA1649A5
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-1E6FEC815102A6DA970E0052
      Guide generation allowed
      false
      Source IDH51-8687B5E680DC3C597EB6D666
      Pediatric
      Applicability
      not_established
      Source IDH51-CB457D0F057232CAC722F434
      Guide generation allowed
      false
      Source IDH51-17CE617989BF26FD6A9D6102
      Neonatal
      Applicability
      not_established
      Source IDH51-B72665EA036DB2095D6F8BB9
      Guide generation allowed
      false
      Source IDH51-BA4C24E73D4FEE51605C0BC5
      Route presence
      Structured dilution
      false
      Source IDH51-C45DB03B7F469FC5F9C756CD
      Iv push
      false
      Source IDH51-DAB2F376885A9819D62CB58D
      Continuous infusion
      false
      Source IDH51-18E43512DB73E5F66726DF0C
      Pediatric source
      false
      Source IDH51-E968A36C0F4B46404B9FFBBB
      Neonatal source
      false
      Source IDH51-9DA363062881E24A223FCC79
      Legacy reference
      Status
      not_available
      Source IDH51-19EAD7EDC3EDEC9D90ED5993
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-53B4AAE5B93C4D15EE280355
      Source files
      1. catalog.json
        Source IDH51-6C0C5F1EB54731ADCA531400
      2. dosing.json
        Source IDH51-1252B6ACA342266AB96D4BF5
      3. legacy-map.json
        Source IDH51-DF02048696DC44DABBA46C4C
      4. review-queue.json
        Source IDH51-2C3983446F1853D721E9849F
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-8470D8C2807052F15FDBBF23
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-594F68E5EE4E9D490E482C8Ccatalog.json
      /records/92/id      		Historical; current review incomplete
      H51-F64756A931816E22606A4620catalog.json
      /records/92/legacy_title      		Historical; current review incomplete
      H51-4FAEAEB2F7E05681417703CBcatalog.json
      /records/92/generic_name      		Historical; current review incomplete
      H51-E898EC5C8DE5853D01508B2Ccatalog.json
      /records/92/class      		Historical; current review incomplete
      H51-3BCD97073B60A8036018AF4Dcatalog.json
      /records/92/subclass      		Historical; current review incomplete
      H51-DDC1DCD2011D5A40FEC42BD5catalog.json
      /records/92/summary      		Historical; current review incomplete
      H51-4C116D25801378FCEBB3A76Dcatalog.json
      /records/92/warnings/0      		Historical; current review incomplete
      H51-BB632C0587108D6DA6DE2733catalog.json
      /records/92/stability_notes/0      		Historical; current review incomplete
      H51-A29A5516FD4032EE55F19B81catalog.json
      /records/92/populations/0      		Historical; current review incomplete
      H51-6B6D15A2ECCF10EFB1818CD2catalog.json
      /records/92/evidence_tier      		Historical; current review incomplete
      H51-206AFBC20030A42A963C668Acatalog.json
      /records/92/high_alert      		Historical; current review incomplete
      H51-17C8EED5CB1EF43F61728D03catalog.json
      /records/92/hazardous      		Historical; current review incomplete
      H51-C6E311A03CC827E68A1F5708catalog.json
      /records/92/status      		Historical; current review incomplete
      H51-D45E4EAF1773EA1F9A543289catalog.json
      /records/92/reviewed      		Historical; current review incomplete
      H51-131BA7FED81EBA0E25D72BA5catalog.json
      /records/92/version_added      		Historical; current review incomplete
      H51-14C9AC35A1DE38F2FCB24D79catalog.json
      /records/92/sources/0      		Historical; current review incomplete
      H51-178C53491CEE224E368E7BC4catalog.json
      /records/92/sources/0/label      		Historical; current review incomplete
      H51-56E5FA2D3E77AB76F36318C6catalog.json
      /records/92/sources/0/url      		Historical; current review incomplete
      H51-266D9C78B30D88FFA4FCFC07catalog.json
      /records/92/sources/0/kind      		Historical; current review incomplete
      H51-1AB47AEBD43CF4168175181Acatalog.json
      /records/92/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-6D9CE9718B3315EFC16E7D02catalog.json
      /records/92/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-9DB8F90E8DD35BB7E239357Bcatalog.json
      /records/92/clinical_release_verification/level      		Historical; current review incomplete
      H51-DE5AF82C8C17F312C1C64BF7catalog.json
      /records/92/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-119323EC67DED8A1B3EF3AD1catalog.json
      /records/92/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-C695D1007E4B64AAB73A3E39catalog.json
      /records/92/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-54B5236536A92D3B143C40B2catalog.json
      /records/92/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-460337CA8AB27D469EB1C6F1catalog.json
      /records/92/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-4BAC23418278D40C91ED303Ccatalog.json
      /records/92/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-18953901FCAC74122AEBA220catalog.json
      /records/92/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-0FB2C492D9BEF0B1E4EBB75Ecatalog.json
      /records/92/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-80CBA38395147821762BAC3Fcatalog.json
      /records/92/clinical_release_verification/note      		Historical; current review incomplete
      H51-A95925C465A3C4C3F39626A4catalog.json
      /records/92/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-A38E94AC6787038FCAAC4056dosing.json
      /records/92/id      		Historical; current review incomplete
      H51-AF7C6747E3EE4F3894240E78dosing.json
      /records/92/generic_name      		Historical; current review incomplete
      H51-D7335067303300DADF1927ABdosing.json
      /records/92/coverage_status      		Historical; current review incomplete
      H51-D977A6BA20AF0CF24FC5015Cdosing.json
      /records/92/package_insert/query_name      		Historical; current review incomplete
      H51-7B147BA6C859DCB21CDBF0D1dosing.json
      /records/92/package_insert/preferred_setid      		Historical; current review incomplete
      H51-5329624DB95234E6C21EE4B3dosing.json
      /records/92/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-F20F182D97650847DF6C98B3dosing.json
      /records/92/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-965813E77E6D4BDECA73B31Edosing.json
      /records/92/package_insert/source_priority      		Historical; current review incomplete
      H51-019DCCBA1811E0AEAE4E2A99dosing.json
      /records/92/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-E9274F898919C9C42CB24EB1dosing.json
      /records/92/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-75CB915461A2CBA441BC33A2dosing.json
      /records/92/package_insert/local_summary_status      		Historical; current review incomplete
      H51-90C37D682DE4D3888CD0341Edosing.json
      /records/92/renal/classification      		Historical; current review incomplete
      H51-1CEB4A93CF34F000928D79BCdosing.json
      /records/92/renal/summary      		Historical; current review incomplete
      H51-FC0832D0B96C9FEEACBEFC26dosing.json
      /records/92/renal/method_note      		Historical; current review incomplete
      H51-6B60607C5C8F3AEEB1BD038Adosing.json
      /records/92/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-76BA05B799782F8FB3D94CE1dosing.json
      /records/92/clinical_review/reviewed      		Historical; current review incomplete
      H51-9F034074BD38E904C9D66C7Bdosing.json
      /records/92/clinical_review/status      		Historical; current review incomplete
      H51-AB7C76EF91DEA0D2803BF18Ddosing.json
      /records/92/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-BB5FC93B9AEEE780BF9F7F73dosing.json
      /records/92/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-9DBC2B91BCB9424DD8BDB396dosing.json
      /records/92/clinical_release_verification/level      		Historical; current review incomplete
      H51-2072EDE87CD024C971A0DF33dosing.json
      /records/92/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-32A3AA023A8E9EBFD831DB38dosing.json
      /records/92/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-A00659FED38B2D568897A35Ddosing.json
      /records/92/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-64809695D9EBD4C1C71A9174dosing.json
      /records/92/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-84A8BEFA0D926F9ECAD81AF4dosing.json
      /records/92/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-E8B0D6B2CBF30539C08D374Fdosing.json
      /records/92/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-3B3392E714B1F9FFA7B1C8E7dosing.json
      /records/92/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-D72469B58C3FA4EE84A53586dosing.json
      /records/92/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-AA4337305F0FB597DFB277DEdosing.json
      /records/92/clinical_release_verification/note      		Historical; current review incomplete
      H51-1E7D2A3BA933AB608BE3404Bdosing.json
      /records/92/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-D1F7EB80D77875BE7A088EAEfirst-look-v5.1.json
      /records/92/id      		Historical; current review incomplete
      H51-477960BC4302894FFE93A60Bfirst-look-v5.1.json
      /records/92/generic_name      		Historical; current review incomplete
      H51-50073B519B0EBAF5B08135EBfirst-look-v5.1.json
      /records/92/class      		Historical; current review incomplete
      H51-42C15E760EE9DC89EB730C82first-look-v5.1.json
      /records/92/subclass      		Historical; current review incomplete
      H51-7ADA61F084ADEC435E390EEAfirst-look-v5.1.json
      /records/92/primary_uses/0      		Historical; current review incomplete
      H51-AAB0A3264827D8B3EF1DD75Cfirst-look-v5.1.json
      /records/92/mechanism      		Historical; current review incomplete
      H51-F8397349F29C9EE70800F46Afirst-look-v5.1.json
      /records/92/mechanism_level      		Historical; current review incomplete
      H51-7DEEBF25D4E512066986A386first-look-v5.1.json
      /records/92/basic_dosing_orientation      		Historical; current review incomplete
      H51-48ACD05A7B1893606E222F3Bfirst-look-v5.1.json
      /records/92/administration_orientation      		Historical; current review incomplete
      H51-E6A91DBAA0C858413E82C228first-look-v5.1.json
      /records/92/renal_and_population_orientation      		Historical; current review incomplete
      H51-C5C82C95AC58A3414925DD1Cfirst-look-v5.1.json
      /records/92/key_safety_orientation/0      		Historical; current review incomplete
      H51-AB4B1A35E05F35266DD055DBfirst-look-v5.1.json
      /records/92/coverage_path      		Historical; current review incomplete
      H51-E4A181800F1C329E1B70EC8Bfirst-look-v5.1.json
      /records/92/coverage_path_label      		Historical; current review incomplete
      H51-127C688B9A28AAE4D941745Afirst-look-v5.1.json
      /records/92/official_label_url      		Historical; current review incomplete
      H51-4F74D64AE9EA5BC313C36087first-look-v5.1.json
      /records/92/legacy_title      		Historical; current review incomplete
      H51-BDCE7E44671FEF0EFFD91CD1first-look-v5.1.json
      /records/92/review_note      		Historical; current review incomplete
      H51-BD400C22D2FBB92B4A5EB627first-look-v5.1.json
      /records/92/search_text      		Historical; current review incomplete
      H51-6E6418E67524BFD5805F4C00first-look-v5.1.json
      /records/92/official_search_url      		Historical; current review incomplete
      H51-1908A5574D2934C9F89554B2first-look-v5.1.json
      /records/92/official_access_mode      		Historical; current review incomplete
      H51-A2EDC4F32AA473AEC3461751first-look-v5.1.json
      /records/92/official_access_url      		Historical; current review incomplete
      H51-8F68FC933FF836F73BFF8B55first-look-v5.1.json
      /records/92/official_search_query      		Historical; current review incomplete
      H51-CDAE8F531B8588616D6FBEDBfirst-look-v5.1.json
      /records/92/official_access_reason      		Historical; current review incomplete
      H51-864272F705D894EDDDFAFB5Bpreparation-assessments-v3.8.json
      /92/id      		Historical; current review incomplete
      H51-D6A030D5226E01E198D7D57Fpreparation-assessments-v3.8.json
      /92/name      		Historical; current review incomplete
      H51-5EC09668539CDCBA9FBC8FE9preparation-assessments-v3.8.json
      /92/brands      		Historical; current review incomplete
      H51-60B82AD5AECDA1AA790608D3preparation-assessments-v3.8.json
      /92/therapeutic_class      		Historical; current review incomplete
      H51-4BAFD1F174CE1A3581C6F2A6preparation-assessments-v3.8.json
      /92/review_version      		Historical; current review incomplete
      H51-6D071B7FB22D49DAB2C8DA93preparation-assessments-v3.8.json
      /92/review_date      		Historical; current review incomplete
      H51-AEE3FB4037D51700CD90F194preparation-assessments-v3.8.json
      /92/release_status      		Historical; current review incomplete
      H51-A98CE5EB42AA14D489F4B37Apreparation-assessments-v3.8.json
      /92/market_status/status      		Historical; current review incomplete
      H51-5F0B841BC96E1E7549DD4FABpreparation-assessments-v3.8.json
      /92/market_status/basis      		Historical; current review incomplete
      H51-D96A64B1C2924D44E29D68EFpreparation-assessments-v3.8.json
      /92/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-DC3FA7C31106E8A983212443preparation-assessments-v3.8.json
      /92/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-890D450EABD273CB429E95A3preparation-assessments-v3.8.json
      /92/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-106CE05665694ED2907ACE3Dpreparation-assessments-v3.8.json
      /92/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-2A08C0CD71401E8101861C96preparation-assessments-v3.8.json
      /92/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-CCFFD0B6CDCE5BAE88741127preparation-assessments-v3.8.json
      /92/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-2DEEF991E353F2E250005EC7preparation-assessments-v3.8.json
      /92/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-284DCDD9C45CA2AA49D83D1Apreparation-assessments-v3.8.json
      /92/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-4B8C5C5772EB882F1B91AFC9preparation-assessments-v3.8.json
      /92/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-B431927010C9BA51C3BB6B4Cpreparation-assessments-v3.8.json
      /92/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-45FA28AE93E6D26902D3F1DCpreparation-assessments-v3.8.json
      /92/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-5C98C8FC047B7B7F35FE2263preparation-assessments-v3.8.json
      /92/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-0E3CDC1F03CB4892EFA70513preparation-assessments-v3.8.json
      /92/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-32D86513BD8F81F1C0CD059Bpreparation-assessments-v3.8.json
      /92/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-9F35B1CAF202D9877F1051C5preparation-assessments-v3.8.json
      /92/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-5F2EF6682D5D0F458C39F553preparation-assessments-v3.8.json
      /92/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-9847130F5130DB51924B7378preparation-assessments-v3.8.json
      /92/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-5F0037EC786529A99498E78Bpreparation-assessments-v3.8.json
      /92/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-776E694321A699820316D2CBpreparation-assessments-v3.8.json
      /92/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-FEEF4EFD8B461F916411E74Bpreparation-assessments-v3.8.json
      /92/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-ABF9E69EE1E8F8C86473451Bpreparation-assessments-v3.8.json
      /92/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-A4B1922CABA926A32BA30A9Bpreparation-assessments-v3.8.json
      /92/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-68A28FA336C07BEB65B55FC0preparation-assessments-v3.8.json
      /92/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-0339336F5316B11C025E8DFFpreparation-assessments-v3.8.json
      /92/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-AC5CAC758E90714ACA1649A5preparation-assessments-v3.8.json
      /92/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-1E6FEC815102A6DA970E0052preparation-assessments-v3.8.json
      /92/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-8687B5E680DC3C597EB6D666preparation-assessments-v3.8.json
      /92/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-CB457D0F057232CAC722F434preparation-assessments-v3.8.json
      /92/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-17CE617989BF26FD6A9D6102preparation-assessments-v3.8.json
      /92/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-B72665EA036DB2095D6F8BB9preparation-assessments-v3.8.json
      /92/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-BA4C24E73D4FEE51605C0BC5preparation-assessments-v3.8.json
      /92/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-C45DB03B7F469FC5F9C756CDpreparation-assessments-v3.8.json
      /92/route_presence/structured_dilution      		Historical; current review incomplete
      H51-DAB2F376885A9819D62CB58Dpreparation-assessments-v3.8.json
      /92/route_presence/iv_push      		Historical; current review incomplete
      H51-18E43512DB73E5F66726DF0Cpreparation-assessments-v3.8.json
      /92/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-E968A36C0F4B46404B9FFBBBpreparation-assessments-v3.8.json
      /92/route_presence/pediatric_source      		Historical; current review incomplete
      H51-9DA363062881E24A223FCC79preparation-assessments-v3.8.json
      /92/route_presence/neonatal_source      		Historical; current review incomplete
      H51-19EAD7EDC3EDEC9D90ED5993preparation-assessments-v3.8.json
      /92/legacy_reference/status      		Historical; current review incomplete
      H51-53B4AAE5B93C4D15EE280355preparation-assessments-v3.8.json
      /92/label_resolution/status      		Historical; current review incomplete
      H51-6C0C5F1EB54731ADCA531400preparation-assessments-v3.8.json
      /92/source_files/0      		Historical; current review incomplete
      H51-1252B6ACA342266AB96D4BF5preparation-assessments-v3.8.json
      /92/source_files/1      		Historical; current review incomplete
      H51-DF02048696DC44DABBA46C4Cpreparation-assessments-v3.8.json
      /92/source_files/2      		Historical; current review incomplete
      H51-2C3983446F1853D721E9849Fpreparation-assessments-v3.8.json
      /92/source_files/3      		Historical; current review incomplete
      H51-8470D8C2807052F15FDBBF23preparation-assessments-v3.8.json
      /92/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top